KN 5001
Alternative Names: KN-5001Latest Information Update: 31 Oct 2025
At a glance
- Originator Rui Therapeutics
- Developer Nanjing Medical University; Rui Therapeutics
- Class Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Lung disorders
Most Recent Events
- 20 Sep 2025 Phase-0 for Lung disorders in China (Parenteral) (NCT07185035)